Skip to main content
. 2019 Dec 31;12:2. doi: 10.1186/s13195-019-0562-4

Table 2.

Biomarkers of neuroinflammation and neurodegeneration in the diagnostic groups

Diagnosis Prion disease AD FTD Controls P
N 101 40 72 40
CHIT1 all (pg/ml), median (IQR) 3669 (1568–8017) 2259 (1603–4944) 2657 (1437–5800) 1409 (783–2537) < 0.001a
WT (pg/ml), median (IQR) 4382 (1874–8311) 2399 (1884–4247) 3706 (1776–7374) 2095 (1226–2948) 0.016a
Het (pg/ml), median (IQR) 4078 (1570–9379) 2065 (1465–5409) 1006 (648–1894) 803 (628–1090) < 0.001a
YKL-40 (ng/ml), median (IQR) 315 (222–453) 240 (176–293) 192 (135–257) 145 (115–161) < 0.001a
GFAP (ng/ml), median (IQR) 1.028 (0.636–1.698) 1.081 (0.534–1.422) 1.065 (0.667–1.422) 0.665 (0.409–0.978) 0.002a
t-tau (pg/ml), median (IQR) 4644 (1977–9223) 698 (491–1013) 253 (179–347) 168 (138–228) < 0.001a
NfL (pg/ml), median (IQR) 7225 (3879–12,188) 1405 (942–1730) 2805 (1382–5158) 595 (430–831) < 0.001a

AD Alzheimer’s disease, CHIT1 chitotriosidase 1, CJD Creutzfeldt-Jakob disease, FTD frontotemporal dementia, GFAP glial fibrillary acidic protein, Het heterozygotes for CHIT1 24-bp duplication, IQR interquartile range, N number, NfL neurofilament light chain protein, t-tau total tau protein, YKL-40 chitinase-3-like protein 1, WT wild type for CHIT1 24-bp duplication

aKruskal-Wallis test